GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avidity Biosciences Inc (NAS:RNA) » Definitions » Interest Coverage

Avidity Biosciences (Avidity Biosciences) Interest Coverage : N/A (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Avidity Biosciences Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Avidity Biosciences's Operating Income for the three months ended in Mar. 2024 was $-77.19 Mil. Avidity Biosciences's Interest Expense for the three months ended in Mar. 2024 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Avidity Biosciences Inc has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for Avidity Biosciences's Interest Coverage or its related term are showing as below:


RNA's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 148.11
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Avidity Biosciences Interest Coverage Historical Data

The historical data trend for Avidity Biosciences's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Avidity Biosciences Interest Coverage Chart

Avidity Biosciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial - - N/A N/A N/A

Avidity Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Avidity Biosciences's Interest Coverage

For the Biotechnology subindustry, Avidity Biosciences's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avidity Biosciences's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avidity Biosciences's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Avidity Biosciences's Interest Coverage falls into.



Avidity Biosciences Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Avidity Biosciences's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Avidity Biosciences's Interest Expense was $0.00 Mil. Its Operating Income was $-235.60 Mil. And its Long-Term Debt & Capital Lease Obligation was $6.21 Mil.

GuruFocus does not calculate Avidity Biosciences's interest coverage with the available data.

Avidity Biosciences's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Here, for the three months ended in Mar. 2024, Avidity Biosciences's Interest Expense was $0.00 Mil. Its Operating Income was $-77.19 Mil. And its Long-Term Debt & Capital Lease Obligation was $5.42 Mil.

GuruFocus does not calculate Avidity Biosciences's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Avidity Biosciences  (NAS:RNA) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Avidity Biosciences Interest Coverage Related Terms

Thank you for viewing the detailed overview of Avidity Biosciences's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Avidity Biosciences (Avidity Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
Executives
Michael F Maclean officer: Chief Financial Officer 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
W. Michael Flanagan officer: Chief Technical Officer C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Teresa Mccarthy officer: Chief Human Resources Officer 10975 N TORREY PINES RD #150, LA JOLLA CA 92037
Arthur A Levin officer: Chief Scientific Officer 1896 RUTHERFORD ROAD, CARLSBAD CA 92008
Sarah Boyce director, officer: President and CEO C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Eric Mosbrooker director C/O HORIZON PHARMA, PLC, ADELAIDE CHAMBERS, PETER STREET, DUBLIN 8 L2 000000
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Jean Jinsun Kim director C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Tamar Thompson director C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Jae B. Kim officer: Chief Medical Officer C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Noreen Henig director C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Lilly Eli & Co 10 percent owner LILLY CORPORATE CENTER, DROP CODE 1094, INDIANAPOLIS IN 46285
Todd C Brady director C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Michael B. Martin director C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037

Avidity Biosciences (Avidity Biosciences) Headlines

From GuruFocus